12:00 AM
May 21, 2001
 |  BioCentury  |  Emerging Company Profile

Glycominds: I think glycan

While many companies and institutions are setting about mapping protein-protein interactions, Glycominds Inc. is taking a different tack in the post-genomic era. The company is developing technologies that map interactions between proteins and complex carbohydrates, or glycans. Glycominds maintains that its carbohydrate chip will make feasible research in this area, which has been hampered by a lack of high throughput technologies.

Glycans affect multiple aspects of a protein's functionality, including folding, cellular localization, circulation half-life and immune response. Thus Glycominds aims to use its Glycomics database and GlycoChip technology to provide partners with drug development services that include target evaluation and toxicity screening.

"In 1998, we asked what the next step would be in the post-genomic world," said CEO Avinoam Dukler. "We decided that it's not enough to know a gene sequence or its protein - you need to know what happens to the protein after it is produced....

Read the full 722 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >